Quanterix Announces Commercialization of p-Tau 217 Test Kit
Quanterix (NASDAQ: QTRX) has announced the commercial availability of its Simoa® p-Tau 217 Planar Kit for Alzheimer's Disease (AD) test development. This kit utilizes p-Tau 217 antibody technology licensed from Eli Lilly and Company and Quanterix's SP-X platform. The move expands access to this technology, allowing customers to develop p-Tau 217 blood tests and services for research use only (RUO).
This development follows Quanterix's March 2022 announcement of license and collaboration agreements with Lilly. The kit is now available immediately, supporting Quanterix's focus on building a global infrastructure for blood-based AD testing. The company aims to lead in Alzheimer's Disease testing for new research and therapies, ultimately advancing patient care and outcomes.
Quanterix (NASDAQ: QTRX) ha annunciato la disponibilità commerciale del suo Simoa® p-Tau 217 Planar Kit per lo sviluppo di test sulla malattia di Alzheimer (AD). Questo kit utilizza la tecnologia degli anticorpi p-Tau 217 concessa in licenza da Eli Lilly and Company e la piattaforma SP-X di Quanterix. Questa iniziativa amplia l'accesso a questa tecnologia, consentendo ai clienti di sviluppare test e servizi sul sangue p-Tau 217 destinati esclusivamente alla ricerca (RUO).
Questo sviluppo segue l'annuncio di Quanterix, nel marzo 2022, di accordi di licenza e collaborazione con Lilly. Il kit è ora disponibile immediatamente, supportando l'obiettivo di Quanterix di costruire un'infrastruttura globale per il testing dell'AD basato sul sangue. L'azienda mira a guidare i test sulla malattia di Alzheimer per nuove ricerche e terapie, con l'obiettivo finale di migliorare le cure e i risultati per i pazienti.
Quanterix (NASDAQ: QTRX) ha anunciado la disponibilidad comercial de su Simoa® p-Tau 217 Planar Kit para el desarrollo de pruebas de la enfermedad de Alzheimer (AD). Este kit utiliza la tecnología de anticuerpos p-Tau 217 licenciada de Eli Lilly and Company y la plataforma SP-X de Quanterix. Este movimiento amplía el acceso a esta tecnología, permitiendo a los clientes desarrollar pruebas de sangre p-Tau 217 y servicios únicamente para uso en investigación (RUO).
Este desarrollo sigue al anuncio de Quanterix en marzo de 2022 sobre acuerdos de licencia y colaboración con Lilly. El kit ya está disponible inmediatamente, apoyando el enfoque de Quanterix en construir una infraestructura global para las pruebas de AD basadas en sangre. La empresa busca liderar en las pruebas de la enfermedad de Alzheimer para nuevas investigaciones y terapias, avanzando así en la atención y los resultados para los pacientes.
퀀터릭스 (NASDAQ: QTRX)는 알츠하이머 병(AD) 테스트 개발을 위한 Simoa® p-Tau 217 Planar Kit의 상업적 가용성을 발표했습니다. 이 키트는 엘리 릴리( Eli Lilly and Company)에서 라이선스 받은 p-Tau 217 항체 기술과 퀀터릭스의 SP-X 플랫폼을 활용합니다. 이 조치는 이 기술에 대한 접근을 확대하여 고객이 p-Tau 217 혈액 테스트 및 연구 전용(RUO) 서비스를 개발할 수 있도록 합니다.
이 개발은 2022년 3월 퀀터릭스가 릴리와의 라이선스 및 협력 계약을 발표한 이후 진행되었습니다. 이 키트는 이제 즉시 사용할 수 있으며, 퀀터릭스가 혈액 기반 AD 테스트를 위한 글로벌 인프라를 구축하는 데 초점을 맞추고 있음을 지원합니다. 이 회사는 새로운 연구와 치료를 위한 알츠하이머 병 테스트에서 선두주자가 되는 것을 목표로 하며, 궁극적으로 환자 치료와 결과를 개선하고자 합니다.
Quanterix (NASDAQ: QTRX) a annoncé la disponibilité commerciale de son Simoa® p-Tau 217 Planar Kit pour le développement de tests sur la maladie d'Alzheimer (AD). Ce kit utilise la technologie des anticorps p-Tau 217 concédée sous licence par Eli Lilly and Company et la plateforme SP-X de Quanterix. Cette initiative élargit l'accès à cette technologie, permettant aux clients de développer des tests sanguins p-Tau 217 et des services uniquement pour un usage de recherche (RUO).
Ce développement fait suite à l'annonce de Quanterix en mars 2022 concernant des accords de licence et de collaboration avec Lilly. Le kit est maintenant immédiatement disponible, soutenant l'objectif de Quanterix de construire une infrastructure mondiale pour les tests sanguins de la maladie d'Alzheimer. La société vise à être leader dans les tests de la maladie d'Alzheimer pour de nouvelles recherches et thérapies, améliorant ainsi les soins et les résultats pour les patients.
Quanterix (NASDAQ: QTRX) hat die kommerzielle Verfügbarkeit seines Simoa® p-Tau 217 Planar Kits für die Testentwicklung bei Alzheimer-Krankheit (AD) angekündigt. Dieses Kit nutzt die p-Tau 217 Antikörpertechnologie, die von Eli Lilly and Company lizenziert ist, sowie die SP-X-Plattform von Quanterix. Dieser Schritt erweitert den Zugang zu dieser Technologie und ermöglicht es den Kunden, p-Tau 217 Bluttests und Dienste nur für Forschungszwecke (RUO) zu entwickeln.
Diese Entwicklung folgt der Ankündigung von Quanterix im März 2022 über Lizenz- und Kooperationsvereinbarungen mit Lilly. Das Kit ist jetzt sofort verfügbar und unterstützt Quanterix' Fokus auf den Aufbau einer globalen Infrastruktur für blutbasierte AD-Tests. Das Unternehmen hat zum Ziel, eine Führungsrolle bei den Tests auf Alzheimer-Krankheit für neue Forschungen und Therapien zu übernehmen, um letztendlich die Patientenversorgung und -ergebnisse zu verbessern.
- Commercialization of Simoa® p-Tau 217 Planar Kit for Alzheimer's Disease testing
- Expansion of access to p-Tau 217 blood test technology
- Collaboration with Eli Lilly and Company for antibody technology
- Immediate availability of the new test kit
- None.
Insights
The commercialization of Quanterix's Simoa® p-Tau 217 Planar Kit marks a significant advancement in Alzheimer's Disease (AD) diagnostics. This move expands access to p-Tau 217 blood testing, a promising biomarker for AD detection. The collaboration with Eli Lilly, leveraging their antibody technology, enhances the test's credibility and potential market impact.
For investors, this development is positive for several reasons:
- It positions Quanterix as a leader in AD blood-based testing, a rapidly growing market.
- The partnership with Lilly, a major pharmaceutical player, adds significant value and validation.
- The immediate availability of the kit could lead to near-term revenue growth.
- Long-term potential exists in both research and clinical applications as AD therapies advance.
However, investors should note that while promising, the RUO status limits immediate clinical use. The path to FDA approval for diagnostic use could be lengthy and uncertain. Overall, this news strengthens Quanterix's position in the neurodegenerative disease diagnostics market, potentially driving future growth and partnerships.
The Simoa® p-Tau 217 Planar Kit represents a crucial step forward in Alzheimer's Disease (AD) research and potential clinical applications. P-Tau 217 is emerging as one of the most specific and sensitive biomarkers for AD and its detection in blood could revolutionize diagnosis and monitoring.
Key points for consideration:
- Blood-based testing is less invasive and more cost-effective than current cerebrospinal fluid (CSF) or PET imaging methods.
- Early and accurate detection of AD pathology could significantly impact clinical trial recruitment and therapeutic interventions.
- The high sensitivity of Quanterix's Simoa platform is important for detecting the low levels of p-Tau 217 in blood.
While the current RUO status limits clinical use, it opens doors for extensive research applications. This could accelerate AD drug development and validation of blood-based biomarkers. The potential for future clinical applications, pending regulatory approvals, presents a significant long-term opportunity for Quanterix in the growing field of AD diagnostics and personalized medicine.
Quanterix expands access to p-Tau 217 blood test kit using antibody technology licensed from Lilly
In March 2022, Quanterix first announced its entry into license and collaboration agreements with Lilly, which specified the initial development of a test for the Eli Lilly Clinical Diagnostics Laboratory (ELCDL), a wholly owned subsidiary of Lilly. Now, with the Simoa® p-Tau 217 Planar Kit, Quanterix will expand access to this technology by selling customers research use only (RUO) instrumentation and consumables to develop p-Tau 217 blood tests and services using p-Tau 217 antibody technology licensed from Lilly. The Simoa® p-Tau 217 Planar Kit will be available immediately.
“We are excited to expand access to high-performing, non-invasive p-Tau 217 testing,” said Masoud Toloue, CEO of Quanterix. “Quanterix continues to focus on building a global infrastructure that supports blood-based testing for Alzheimer’s Disease. With the broader availability of the Lilly antibody technology and Simoa’s sensitivity, we are prepared to lead Alzheimer's Disease testing for groundbreaking new research and therapies, ultimately supporting the advancement of care and outcomes for patients.”
“Lilly is committed to enabling and supporting the development of high-quality diagnostics for Alzheimer’s Disease,” said Anthony Sireci, M.D., Msc., Head of the Diagnostics Development & Commercialization for Lilly. “We’re excited about collaborating with Quanterix to advance blood-based biomarkers and licensing Lilly technology to achieve this aim.”
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240930378392/en/
Media Contact:
PAN Communications
Maya Nimnicht
(510) 334-6273
quanterix@pancomm.com
Investor Relations Contact:
Francis Pruell, Quanterix
(508) 789-1725
ir@quanterix.com
Source: Quanterix Corporation
FAQ
What is the new product Quanterix (QTRX) has announced for commercialization?
How does the Simoa® p-Tau 217 Planar Kit from Quanterix (QTRX) work?
When did Quanterix (QTRX) enter into license and collaboration agreements with Eli Lilly?
What is the intended use of the Simoa® p-Tau 217 Planar Kit from Quanterix (QTRX)?
